Gilead Sciences' 3Q 2026 HIV product sales rose 18% year-over-year to $6.2 billion, driven by higher demand in HIV prevention and improved average realized prices. Descovy, the company's prevention-focused treatment, saw revenue surge 49% to $1.0 billion, while flagship treatment Biktarvy grew 10% to $4.1 billion. The strong performance in the HIV business prompted management to raise full-year base business revenue guidance, bringing total increases to $1.6 billion since the start of 2026, the company said. HIV prevention sales nearly doubled compared with the prior year
This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments